FDA Drug recall D-0320-2022
NOREPINEPHRINE, 4 mg per 250 mL, (18 mcg per mL) in 0.9% Sodium Chloride Injection, Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903,…
- FDA Drug
- Class II
- terminated
- Published 2022-01-05
On 2022-01-05 the FDA classified a Class II recall of NOREPINEPHRINE, 4 mg per 250 mL, (18 mcg per mL) in 0.9% Sodium Chloride Injection, Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903,… by Sterrx, citing lack of Assurance of Sterility.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0320-2022 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2021-11-12 |
| Published | 2022-01-05 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Sterrx |
| Distribution | US |
Product
NOREPINEPHRINE, 4 mg per 250 mL, (18 mcg per mL) in 0.9% Sodium Chloride Injection, Rx only, SterRx, 141 Idaho Ave., Plattsburgh, NY 12903, NDC 70324-651-01.
Reason
Lack of Assurance of Sterility
Identifiers
| code_info | S20415/BKY 12-Nov-21 S20418/BLB 13-Nov-21 S20452/BMI 5-Dec-21 S20463/BMT 9-Dec-21 S20464/BMU 18-Dec-21 S20478/BNF…S20415/BKY 12-Nov-21 S20418/BLB 13-Nov-21 S20452/BMI 5-Dec-21 S20463/BMT 9-Dec-21 S20464/BMU 18-Dec-21 S20478/BNF 23-Dec-21 S21021/BOI 6-Jan-22 S21033/BOU 20-Jan-22 S21047/BPH 21-Jan-22 S21059/BPU 28-Jan-22 S21094/BRE 18-Feb-22 S21117/BSB 3-Mar-22 S21118/BSC 10-Mar-22 S21138/BSW 17-Mar-22 S21227/BWA 7-May-22 S21239/BWK 12-May-22 S21279/BXW 5-Jun-22 S21295/BYL 16-Jun-22 S21298/BYO 18-Jun-22 S21339/BZZ 16-Jul-22 S21346/CAF 21-Jul-22 S21355/CAO 28-Jul-22 S21370/CBD 4-Aug-22 S21372/CBF 7-Aug-22 S21438/CDS 4-Sep-22 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0320-2022%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.